Ocrelizumab in patients with Relapsing-Remitting Muscular Sclerosis
(RRMS)
Trial Status
Open for Enrollment
What is the Purpose of this Study?
To investigate if the effect of ocrelizumab
given at 600 mg intravenously is superior to Rebif as measured by the
total amount of relapses.
Who is Eligible to Participate?
Patients 18-55 years of age diagnosed
with MS and have had two documented relapses within the last two years.
Patients must have neurological stability for at least 30 days prior
to screening and have an EDSS of 0-5.5 inclusive. Patients can not be
on any beta interferons, or received previous treatment with rituximab.
Patients must also meet all other inclusion and exclusion criteria explained
in detail by study coordinator.
What is involved in this Study?
Each group will receive either active
Rebif and placebo ocrelizumab or placebo Rebif and active Ocrelizumab.
This is a double blinded study, patients will be randomized in 1:1 fashion.
A more in depth treatment regimen will be explained in greater detail
by the study coordinator.
How long is the Study?
All patients will undergo 96 weeks of study treatment
representing two treatment cycles every 24 weeks. The total study duration
is approximately 96 weeks.
For More Information Contact: Lynne E. Flynn,
CCRC, study coordinator, at 602-258-2863 or lynneflynn@pnal.net or
call the Main line at 602-258-3354
